Lixisenatide 产品活性：Lixisenatide 是一种胰高血糖素样肽-1 受体 (GLP-1 receptor ) 激动剂。Lixisenatide 通过下调促炎细胞因子、阻断细胞信号通路抑制炎症反应。Lixisenatide 通过将巨噬细胞重编程为 M2 表型，减轻炎症，从而减少 Apoe−/− Irs2+/− 小鼠的粥样斑块大小和不稳定性。 产品来源： https://www.medchemexpress.cn/Lixisenatide.html 研究领域：GPCR/G Protein | MAPK/ERK Pathway | PI3K/Akt/mTOR | Metabolic Enzyme/Protease 作用靶点：GCGR | MEK | Akt | MMP | JNK In Vitro: Lixisenatide (100 μM, 24 h) inhibits the Aβ25-35-induced cytotoxicity on cultured hippocampal cells. . Lixisenatide (100 μM, 24 h) relieves the Aβ25-35-induced suppression of the Akt-MEK1/2 signaling pathway on cultured hippocampal cells . Lixisenatide (10-20 μM, 48 h) ameliorates IL-1β-induced oxidative stress, mitochondrial dysfunction, and apoptosis in fibroblast-like synoviocytes (FLSs) . Lixisenatide (10-20 μM, 48 h) reduces IL-1β-induced expression of MMPs and inhibits activation of proinflammatory pathways by IL-1β in FLSs. Lixisenatide (10-20 μM, 6 h) reduced oxygen-glucose deprivation/reperfusion (OGD/R)-induced generation of ROS in HUVECs. In Vivo: Lixisenatide (10 μg/kg, Subcutaneous injection, once a day for a month) diminishes the atherosclerosis burden and produces more stable plaques . Lixisenatide (10 μg/kg, Subcutaneous injection, once a day for a month) decreases systemic inflammation in atherogenic-diet-fed Apoe−/− Irs2+/− mice. Lixisenatide (1 nmol/kg, Intraperitoneal injection, once a day for 14 days) afford renoprotective effects on experimental early diabetic nephropathy in a low dose. 相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | Peptide Library | Deferoxamine mesylate | Trametinib | SP600125 | MK-2206 dihydrochloride | PD98059 | SC79 | Mirdametinib | Doxycycline hyclate | Yoda 1 | Capivasertib | U0126-EtOH | Afatinib | Semaglutide | Anisomycin | T-5224 | Exendin-4 | Selumetinib | Ipatasertib | Liraglutide | JNK-IN-8 | Binimetinib | Cobimetinib | Ilomastat | Chloramphenicol | Honokiol | Glucagon (1-29), bovine, human | Astragaloside IV | Oridonin | Exendin(9-39) amide 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。